Are there any evidence‑based interventions, such as vitamins or supplements, that can eradicate human papillomavirus infection in women aside from vaccination?

No Evidence-Based Interventions Beyond Vaccination for HPV Eradication

There are no guideline-endorsed vitamins, supplements, or other interventions proven to eradicate HPV infection in women besides vaccination. The most authoritative clinical guidelines explicitly state that HPV infections themselves are not treated—only the lesions they cause 1.

What the Guidelines Say

The ACIP (Advisory Committee on Immunization Practices) and CDC guidelines are unequivocal: "HPV infections are not treated; treatment is directed at the HPV-associated lesions" 1. Treatment options focus on removing visible disease through:

• Cryotherapy
• Electrocautery
• Laser therapy
• Surgical excision
• Topical pharmacologic agents (for genital warts only)

These interventions may reduce but probably do not eliminate infectiousness 1.

The Natural History Argument

Guidelines emphasize that the majority of HPV infections (approximately 90%) are transient and resolve spontaneously within 2 years 2. Only 10% persist, and only 1% of infected women develop neoplastic lesions 2. This natural clearance rate is critical context—most infections don't require intervention because the immune system handles them independently.

Why No Screening for Subclinical Infection

Multiple guidelines from 1993-2007 consistently state: "Screening for subclinical genital HPV infection using DNA tests or acetic acid is not recommended" 3, 4. Management decisions should not be based on HPV DNA tests alone 3. This reflects the lack of proven interventions to alter infection outcomes.

Emerging Research Evidence (Not Yet Guideline-Supported)

While guidelines provide no support, recent research studies have explored various supplements. These remain investigational and are not standard of care:

AHCC (Active Hexose Correlated Compound)

A 2022 randomized, double-blind, placebo-controlled trial (N=50) showed 63.6% of women cleared persistent high-risk HPV after 6 months of AHCC supplementation (3g daily), versus 10.5% on placebo 5. However, this is a single small study requiring replication before clinical adoption.

EGCG + Folic Acid + Vitamin B12 + Hyaluronic Acid

A 2025 clinical study (N=106) reported 85.8% viral clearance after 6 months of combined supplementation 6. A 2026 case series showed similar results in 6 male patients 7. These are uncontrolled observational studies with significant methodological limitations.

Vitamin D

Multiple recent studies suggest associations between vitamin D supplementation and improved HPV clearance 8, 9. A 2025 meta-analysis found vitamin D supplementation reduced CIN2/3 lesions (SMD = 0.81, GRADE: High) 8. However, these are primarily observational data that cannot rule out reverse causation 10.

Folate and Vitamin B12

Lower folate levels were reported in HPV-positive women in 7 of 9 studies reviewed 10. A 2025 meta-analysis showed protective associations (SMD = 0.80, GRADE: High) 8. Again, causality remains unproven.

Critical Limitations of Supplement Research

None of these supplement studies have been incorporated into clinical practice guidelines. The evidence suffers from:

• Small sample sizes
• Lack of long-term follow-up
• Absence of replication in diverse populations
• Unclear mechanisms of action
• Potential for reverse causation (low vitamins may be consequence, not cause)
• No data on prevention of cervical cancer or mortality

What Actually Works: The Evidence-Based Approach

Prevention

1. HPV vaccination (quadrivalent, bivalent, or nonavalent) for females aged 11-12 years, with catch-up through age 26 11, 12, 13
2. Consistent condom use reduces HPV acquisition by 70% in newly sexually active women 1
3. Abstinence or monogamous relationships with uninfected partners 1

Surveillance and Early Detection

Cervical cancer screening remains essential even after vaccination 11. Guidelines recommend:

• Pap testing starting within 3 years of sexual activity or by age 21 1
• Women <30 years: annual screening
• Women ≥30 years with 3 consecutive normal Paps: every 2-3 years 1

This screening-and-treatment approach has dramatically reduced cervical cancer mortality in developed countries 1.

Clinical Bottom Line

For women with HPV infection, the evidence-based management is watchful waiting with appropriate cervical cancer screening, not supplementation. Most infections clear spontaneously. For those with persistent infection causing dysplasia, treatment targets the lesions, not the virus.

While emerging supplement research is intriguing, it remains preliminary and cannot be recommended as standard care. The proven interventions remain vaccination for prevention and screening for early detection of disease—not viral eradication strategies.